34 results about "CD1" patented technology

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR $g(a) chain, except the transmembrane domain thereof, and (ii) all or part of a TCR $g(b) chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR, characterized in that the sTCR recognizes a CD1-antigen complex, a bacterial superantigen or a peptide-MHC / superantigen complex.

Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including: methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample; methods for isolating such CD1-presented antigens and isolated antigens; vaccines containing CD1-presented antigens and vaccination methods; methods of blocking CD1 antigen presentation; methods of identifying and / or isolating CD1 blocking agents and the isolated CD1 blocking agents; methods of inducing CD1 expression; and T-cells for use in the methods disclosed herein.

Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting an NKT cell with a bacterial glycolipid complexed with a CD1 molecule to activate the NKT cell. The bacterial glycolipid may be derived from a member of the Class Alphaproteobacteria.

The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.

The invention discloses a human T-lymphoblastic leukemia / lymphoma cell line and its construction method and application. The human T-lymphoblastic leukemia / lymphoma cell line is named as human T-lymphoblastic leukemia / lymphoma ZYXY-T1, and was deposited in the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on January 20, 2021, with a deposit number It is CCTCC NO:C202143. The present invention is obtained by extracting and separating mononuclear cells from the peripheral blood of clinical human T-lymphoblastic leukemia / lymphoma patients, and culturing them in vitro for continuous natural passage. This leukemia cell line has the typical surface antigen expression characteristics of ETP‑ALL, that is, it does not express CD1α, CD5, CD8, highly expresses the stemness marker CD34, has good in vitro proliferation ability and in vivo tumorigenesis ability, and can be used as a study on the development mechanism of ETP‑ALL Research and individualized treatment In vitro research cell materials can also be used for in vivo and in vitro research ETP‑ALL drug screening, evaluation, and guidance for clinical medication.

The invention relates to an image-identification-based automatic geometric correction method for curved surface projection. A camera is arranged to face the center of a projection screen and is connected to a computer; a projector projects a projection image including at least four identifiable positioning green square blocks, the camera collects the image and identifies and localizes a color block position, and a homography matrix H between camera image space and projector image space is calculated; a full-black image is projected on the projector, N*N infrared laser pens are used for projection at horizontal and vertical equally-dividing points of a target projection region of the projection screen to form an N-row N-column laser dot matrix; the camera collects one frame of image, identifies the location of an infrared laser dot matrix location, and records a location set Cd{Cd1, Cd2...Cdi}; according to the homography matrix H, back calculation of a location set Ps of the intersection point location set Cd in the image space of the projector is carried out; a Bezier surface using as a projection curved surface is established in the image space of the projector by using opengl, the projection picture is mapped to the opengl Bezier surface in a texture manner, the location set Ps of the image space of the projector is used as N-row N-column control points of three-times Bezier surface to form a projection curved surface, thereby completing geometric correction. Therefore, non-linear curved surface geometric correction can be processed automatically; equipment is available; and the effect is good.

The invention discloses a doped core-shell nanometer material and a preparation method thereof. The chemical general formula of the material is Cd1-xMxSe / ZnS, and M is one of Cr, Mn, Fe, Co, Ni, Cu, Zn, Bi, Ce, Pr, Nd, Eu and Er. The preparation method comprises the steps that 1, a positive ion aqueous solution is prepared, a surface finishing agent is added, the pH value is adjusted, and positive ion precursor liquid is obtained; 2, Se powder is added to a NaBH4 aqueous solution, a reaction is carried out under protection of nitrogen, and negative ion precursor liquid is obtained; 3, at constant temperature, the negative ion precursor liquid and the positive ion precursor liquid are mixed for reacting, and core layer Cd1-xMxSe nanocrystalline precursor liquid is obtained; 4, a Zn<2+> and S<2-> ion aqueous solution is added through titrimetry, the reaction continues to be carried out, cooling is carried out under protection of nitrogen, detergent is added for centrifugation and washing, and the doped core-shell nanometer material is obtained. The material is free of toxins or low in toxin, and the preparation method is simple in step; the size is easy to control, and large-scale production can be achieved. A novel method is provided for preparing efficient and cheap biomedical materials.

The invention discloses a Streptococcus suis SBP_bac_5 gene deletion strain as well as a construction method and application thereof. The deletion strain is SSΔSBP_bac_5 without resistance marker, and the preservation number is: CGMCC No.10076. The invention adopts the RecA homologous recombination system and uses the temperature-sensitive suicide plasmid pSET4s as a carrier to knock out the gene encoded by the Streptococcus suis type 7 strain SBP_bac_5, and destroys the expression of the SBP_bac_5 protein. The S. suis 7 type SS△SBP_bac_5 strain obtained by the invention is weaker in toxicity than the parent strain and safe for animals. Vaccines were made with recombinant bacteria and CD1 mice were immunized. The experimental results showed that the recombinant Streptococcus suis vaccine could effectively induce the body to produce a specific humoral immune response, so that the immunized mice could obtain protection against S. suis challenge, and could Effectively prevent the proliferation of bacteria in the body. The engineering bacterium obtained by the invention provides an important basis for the development of the Streptococcus suis vaccine.

The invention discloses a method for preparing and purifying a radioresistant peptide or a mutant protein thereof. The method can significantly improve the protein purity and is convenient for industrial production. The present invention also provides a radioresistant peptide mutein, which is based on the radioresistant peptide protein CBLB502, and replaces the amino acid sequence between the ND1 and CD1 domains, and the mutein has SEQ ID NO: The stability of the amino acid sequence shown in 2 is significantly better than that of the CBLB502 protein in the prior art.

The invention discloses an integrated igniter control circuit; a magnetor provides alternating current, and then an ignition coil ignites through the integrated igniter control circuit. The integrated igniter control circuit comprises a microchip; the control circuit is connected to the output end of the ignition coil; when a positive pulse signal arrives, ZPC provides the signal to a single chip microcomputer; when a negative pulse signal arrives, FPC provides the signal to the single chip microcomputer; the single chip microcomputer processes the ZPC and FPC signal by the microchip to output an OUT signal so as to control a silicon controlled SCR1 to discharge positive electricity, so that energy stored in the capacitor C3 is released, and thereby the purpose of providing energy to the ignition coil is achieved, and low voltage (200V) is transformed to be high voltage (21KV) by the ignition coil to discharge to ignite oil and gas mixture in a gasoline engine, thus achieving the purpose of ignition; the microchip is added at the control part of the igniter, the igniter is under programmed control in a CD1 energy storage mode, and a curve for advance angles of ignition is traced out through programming according to power consumption of the engine, so that oil consumption is saved and ignition energy is large.